Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 30 symbols : Snynf save search
Money on the Move: March 23-29
Published: 2022-03-30 (Crawled : 22:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
INO 3 d | $9.82 -3.72% 160K
|
Health Technology
|
| O: -1.05%
H: 2.12%
C: -3.44%
Cold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight
Published: 2022-03-30 (Crawled : 16:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 4.29%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.05%
H: 0.63%
C: -0.1%
disease growth market
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseResults anticipated in H2 2022
Published: 2022-03-30 (Crawled : 16:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 1.05%
H: 0.34%
C: 0.0%
acer-801 treatment trial therapeutics enroll phase 2b
Dragonfly Therapeutics Expands Clinical Leadership Team, Appointing Dr. Hesham Aboshady as Head of Safety & Pharmacovigilance and Rajesh Israni as Head of Regulatory Affairs
Published: 2022-03-30 (Crawled : 15:00) - prnewswire.com
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
therapeutics
Civica is Rallying Leaders to Make Insulin Affordable by 2024
Published: 2022-03-30 (Crawled : 13:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
insulin
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
Published: 2022-03-30 (Crawled : 12:20) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.59%
H: 0.75%
C: 0.27%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
REPL | $6.63 -4.88% 140K
|
Health Technology
|
| O: 0.72%
H: 4.53%
C: 1.25%
program immunotherapy
BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Published: 2022-03-30 (Crawled : 11:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
BNTX | $86.81 0.74% 230K
|
Health Technology
|
| O: 7.08%
H: 2.42%
C: -5.32%
results
Press Release: Availability of the Q1 2022 Memorandum for modelling purposes
Published: 2022-03-30 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.